Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($2.07), $1.79 worse than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.